In the present article, we characterize the effect of pharmacological modulators of the eIF2α–ATF4 pathway, and of TRIB3, an endogenous inhibitor of ATF4, on the gene expression and viability of HepG2 human hepatoma cells exposed to bortezomib. This evidence concerns the gene TRIB3 and hepatocellular carcinoma.